Literature DB >> 4076325

Effect of verapamil on renal plasma flow, glomerular filtration rate and plasma angiotensin II, aldosterone and arginine vasopressin in essential hypertension.

S S Sørensen, O O Thomsen, H Danielsen, E B Pedersen.   

Abstract

Renal plasma flow, glomerular filtration rate plasma angiotensin II, aldosterone and arginine vasopressin, free water clearance, blood pressure and body weight in 11 patients with mild to moderate hypertension were determined at the end of consecutive 6 week periods of administration of placebo and verapamil up to 120 mg t.i.d. Verapamil induced a 10% reduction in diastolic blood pressure. Compared with placebo none of the other parameters measured changed after treatment with verapamil. There was no significant correlation between blood pressure and arginine vasopressin in plasma. It is concluded that verapamil reduced blood pressure by vasodilatation without activation of the counterbalancing mechanisms commonly seen after treatment with vasodilating drugs, i.e. tachycardia, activation of the renin-angiotensin-aldosterone system, water and salt retention, and without affecting renal haemodynamics. AVP does not seem to be involved in blood pressure regulation in mild to moderate essential hypertension.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4076325     DOI: 10.1007/BF00544077

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  18 in total

1.  Measurement of angiotensin II in human plasma: technical modifications and practical experience.

Authors:  A M Kappelgaard; M D Nielsen; J Giese
Journal:  Clin Chim Acta       Date:  1976-03-15       Impact factor: 3.786

2.  Glomerular filtration rate, renal plasma flow and filtration fraction in living donors before and after nephrectomy.

Authors:  P E Skov; H E Hansen
Journal:  Acta Med Scand       Date:  1974 Jan-Feb

3.  Antihypertensive and renal effects of orally administered verapamil.

Authors:  G Leonetti; C Sala; C Bianchini; L Terzoli; A Zanchetti
Journal:  Eur J Clin Pharmacol       Date:  1980-11       Impact factor: 2.953

4.  Role of vasopressin in cardiovascular homeostasis and hypertension.

Authors:  C I Johnston; M Newman; R Woods
Journal:  Clin Sci (Lond)       Date:  1981-12       Impact factor: 6.124

5.  Vasopressin and blood pressure.

Authors:  F C Bartter
Journal:  N Engl J Med       Date:  1981-04-30       Impact factor: 91.245

6.  Effect of indapamide on renal plasma flow, glomerular filtration rate and arginine vasopressin in plasma in essential hypertension.

Authors:  E B Pedersen; H Danielsen; E S Spencer
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

7.  Development and clinical application of a new method for the radioimmunoassay of arginine vasopressin in human plasma.

Authors:  G L Robertson; E A Mahr; S Athar; T Sinha
Journal:  J Clin Invest       Date:  1973-09       Impact factor: 14.808

8.  Vasopressin elevation in essential hypertension and increased responsiveness to sodium intake.

Authors:  A W Cowley; W C Cushman; E W Quillen; M M Skelton; H G Langford
Journal:  Hypertension       Date:  1981 May-Jun       Impact factor: 10.190

9.  Antihypertensive and humoral effects of verapamil and nifedipine in essential hypertension.

Authors:  G Muiesan; E Agabiti-Rosei; M Castellano; C L Alicandri; L Corea; R Fariello; M Beschi; G Romanelli
Journal:  J Cardiovasc Pharmacol       Date:  1982       Impact factor: 3.105

10.  Vasopressor role of ADH in the pathogenesis of malignant DOC hypertension.

Authors:  J Möhring; B Möhring; M Petri; D Haack
Journal:  Am J Physiol       Date:  1977-03
View more
  7 in total

1.  Sustained release verapamil in renal hypertension.

Authors:  H Eiskjaer; E B Pedersen; L M Rasmussen; B Jespersen
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

Review 2.  Verapamil. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension.

Authors:  D McTavish; E M Sorkin
Journal:  Drugs       Date:  1989-07       Impact factor: 9.546

Review 3.  Effects of calcium antagonists on the hypertensive kidney.

Authors:  G P Reams; J H Bauer
Journal:  Cardiovasc Drugs Ther       Date:  1990-10       Impact factor: 3.727

Review 4.  Isradipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiovascular disease.

Authors:  A Fitton; P Benfield
Journal:  Drugs       Date:  1990-07       Impact factor: 9.546

5.  Is renal protection with calcium antagonists possible?

Authors:  P García-Cosmes; A Mortezo; J M López-Novoa; J F Macías-Núñez
Journal:  Drugs       Date:  1992       Impact factor: 9.546

Review 6.  Do calcium channel blockers have renal protective effects?

Authors:  G P Reams
Journal:  Drugs Aging       Date:  1994-10       Impact factor: 3.923

Review 7.  How Do Antihypertensive Drugs Work? Insights from Studies of the Renal Regulation of Arterial Blood Pressure.

Authors:  Holly Digne-Malcolm; Matthew C Frise; Keith L Dorrington
Journal:  Front Physiol       Date:  2016-07-29       Impact factor: 4.566

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.